tuneTypical Dose
325 to 650 mg per protein-containing meal, taken at the start of eating. Some practitioners recommend gradual upward titration from one capsule.
Supplement
Betaine HCl
Betaine hydrochloride
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Gastric pH reduction occurs within minutes of dissolution. The pharmacokinetic effect is immediate and transient, lasting roughly 70 to 80 minutes per dose. There is no cumulative or build-up effect.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Betaine HCl is a supplemental source of hydrochloric acid used to temporarily lower gastric pH, primarily by people who suspect they have low stomach acid. Clinical evidence for symptom improvement is essentially absent.
Betaine HCl dissociates in the stomach to release hydrochloric acid, and pharmacokinetic studies in healthy volunteers confirm it can transiently and significantly lower gastric pH. That mechanistic step is real. What is missing is any controlled human trial testing whether this pH reduction actually translates into better digestion, reduced bloating, or improved nutrient absorption in people with naturally occurring hypochlorhydria. The clinical use case rests almost entirely on physiological reasoning and practitioner tradition rather than on trial evidence. Safety concerns are more concrete than the efficacy evidence, particularly the risk of gastric mucosal damage when combined with NSAIDs, aspirin, or corticosteroids, and the danger of adding acid to a stomach that may not actually need it.
Betaine HCl dissociates in the stomach to release hydrochloric acid, transiently lowering gastric pH. This can improve the acid-dependent steps of digestion including protein denaturation, pepsin activation, and mineral solubility. The acid-delivery mechanism is pharmacokinetically confirmed in human studies, but its translation to clinical symptom improvement has not been tested in any controlled trial.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Transient gastric pH reduction in people with low stomach acid output
Secondary Outcomes
- Potential improvement in protein digestion and mineral absorption in genuinely hypochlorhydric individuals (theoretical, untested in RCTs)
- Restoration of pH-dependent drug absorption in pharmacologically induced hypochlorhydria (confirmed in pharmacokinetic studies)
Safety
Contraindications and Interactions
Contraindications
- Active peptic ulcer or duodenal ulcer
- Active gastritis or erosive esophagitis
- GERD or Barrett esophagus
- Concurrent NSAID, aspirin, or corticosteroid use
- Pregnancy
- Lactation
- Children
Side effects
- Epigastric burning or warmth
- Heartburn
- Nausea
- Gastric discomfort or cramping
Interactions
- NSAIDs (ibuprofen, naproxen, diclofenac, etc.)
- Aspirin
- Corticosteroids (oral)
- Proton pump inhibitors
- H2 receptor antagonists
- PH-dependent medications
Avoid if
- You have any history of peptic ulcer, duodenal ulcer, gastritis, or esophageal conditions
- You take NSAIDs, aspirin, or oral corticosteroids regularly
- You have not had persistent digestive symptoms evaluated by a clinician
- You are pregnant, breastfeeding, or under 18
- You are currently taking proton pump inhibitors or H2 blockers without clinician guidance
Evidence
Study-level References
betaine-hcl-SRC-001Open-label pharmacokinetic pilot study
Sourceopen_in_newYago MR, Frymoyer AR, Smelick GS, Frassetto LA, Budha NR, Dresser MJ, Ware JA, Benet LZ. Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. Mol Pharm. 2013;10(11):4032-7. PMID: 23980906.
Population: Healthy adult volunteers with normal baseline gastric acid secretion (fasting gastric pH below 4), given rabeprazole to induce hypochlorhydria
Dose protocol: 1500 mg betaine HCl single dose under fasting conditions with continuous Heidelberg capsule pH monitoring in 6 healthy volunteers with rabeprazole-induced hypochlorhydria.
Key findings: Gastric pH dropped 4.5 units (from 5.2 to 0.6) within about 6 minutes. Reacidification lasted roughly 70 to 80 minutes. Effect was transient and self-limiting.
Notes: The foundational pharmacokinetic study confirming the acid-delivery mechanism. Very small sample, drug-induced rather than natural hypochlorhydria, and no symptom outcomes measured.
Paper content
This pilot study demonstrated that a single 1500 mg dose of betaine HCl can transiently and significantly re-acidify the stomach in healthy volunteers with pharmacologically induced hypochlorhydria. Gastric pH dropped rapidly, reaching below 3 within about 6 minutes on average, and remained low for roughly 73 minutes. The reacidification was temporary and self-limiting. This study was designed primarily to evaluate betaine HCl as a tool for restoring gastric acidity in the context of pH-dependent drug absorption, not to evaluate digestive symptom improvement. The sample size was very small (n=6) and hypochlorhydria was drug-induced rather than naturally occurring.
betaine-hcl-SRC-002Randomized, single-dose, three-way crossover pharmacokinetic study
Sourceopen_in_newYago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ware JA, Dresser MJ. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. Clin Pharmacol Ther. 2014;96(5):505-12. PMID: 25274610.
Population: Healthy adult volunteers with normal gastric acid secretion at baseline
Dose protocol: 1500 mg betaine HCl co-administered with dasatinib 100 mg after rabeprazole pretreatment in a randomized three-way crossover with 10 healthy volunteers.
Key findings: Betaine HCl fully restored dasatinib absorption that had been suppressed by acid-reducing medication, confirming that the pH reduction is functionally meaningful for drug bioavailability.
Notes: Supports the acid-delivery mechanism through a pharmacokinetic endpoint. Primary relevance is to drug absorption, not to digestive symptoms.
Paper content
This randomized crossover study in 10 healthy volunteers confirmed that rabeprazole-induced hypochlorhydria dramatically reduced dasatinib bioavailability, and that co-administration of 1500 mg betaine HCl fully restored dasatinib exposure to control levels. The primary relevance to betaine HCl supplementation is pharmacokinetic, demonstrating that betaine HCl delivers enough acid to meaningfully lower gastric pH and alter the absorption of pH-sensitive drugs. The study was not designed to assess digestive symptom outcomes and enrolled healthy volunteers with drug-induced rather than naturally occurring hypochlorhydria.
betaine-hcl-SRC-003Narrative review
Sourceopen_in_newGuilliams TG, Drake LE. Meal-Time Supplementation with Betaine HCl for Functional Hypochlorhydria: What is the Evidence? Integr Med (Encinitas). 2020;19(1):32-36. PMID: 32549862.
Population: General adult population with suspected functional hypochlorhydria. The review discusses populations including older adults, PPI users, and people with non-specific digestive complaints attributed to low stomach acid.
Dose protocol: Narrative review covering doses from 325 mg to 3000 mg or more per meal as used in clinical practice. No original dose-response data.
Key findings: Concluded that while the mechanistic logic for betaine HCl in hypochlorhydria is plausible, clinical evidence does not yet support confident recommendations. Highlighted the absence of controlled trials for symptom outcomes.
Notes: The most honest and comprehensive review of the evidence gap. Essential for understanding why betaine HCl gets a D tier despite having a clear mechanism.
Paper content
This narrative review examined the evidence base for betaine HCl supplementation in functional hypochlorhydria. The authors noted that while the integrative and functional medicine community has long used betaine HCl supplements for people with suspected low stomach acid, the direct clinical evidence supporting symptom improvement is remarkably thin. The review acknowledged the pharmacokinetic evidence that betaine HCl can transiently lower gastric pH but highlighted the absence of randomized controlled trials testing betaine HCl for digestive symptom relief, nutrient absorption improvement, or any patient-relevant clinical outcome in people with naturally occurring hypochlorhydria. The authors discussed the physiological rationale for supplemental acid, the challenge of diagnosing functional hypochlorhydria in practice, and the risks of using betaine HCl inappropriately. They concluded that while the mechanistic logic is plausible, the clinical evidence does not yet support confident recommendations.
betaine-hcl-SRC-004Randomized controlled crossover trial
Sourceopen_in_newSurofchy DL, Frassetto LA, Benet LZ. Food, Acid Supplementation and Drug Absorption - a Complicated Gastric Mix: a Randomized Control Trial. Pharm Res. 2019;36(11):155. doi:10.1007/s11095-019-2693-5. PMID:31485804.
Population: Healthy adult volunteers.
Dose protocol: Escalating betaine HCl doses (1500, 3000, 4500 mg) with continuous gastric pH monitoring after food intake in 9 healthy volunteers.
Key findings: Food buffered gastric pH to about 3.2. Without supplementation, pH returned to baseline in 50 minutes. 4500 mg betaine HCl accelerated reacidification to 17 minutes, showing that practical meal-time doses need to be substantially higher than commonly recommended.
Notes: Critical dose-response data showing that commonly recommended betaine HCl doses may be insufficient during meals.
Paper content
This randomized crossover trial in 9 healthy volunteers tested escalating doses of betaine HCl (1500, 3000, and 4500 mg) for gastric reacidification after food intake. Food elevated gastric pH to approximately 3.2, and without supplementation pH returned to baseline in about 50 minutes. The highest betaine HCl dose (4500 mg) accelerated reacidification to about 17 minutes. The study demonstrates that food significantly buffers gastric acid and that meaningful reacidification during meals requires substantially higher betaine HCl doses than is commonly recommended.
betaine-hcl-SRC-005Randomized, single-dose, 3-period crossover trial
Sourceopen_in_newFaber KP, Wu HF, Yago MR, Xu X, Kadiyala P, Frassetto LA, Benet LZ. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. Pharm Res. 2017;34(3):619-628. doi:10.1007/s11095-016-2090-2. PMID:28028768.
Population: Healthy adult volunteers.
Dose protocol: 1500 mg betaine HCl co-administered with atazanavir/ritonavir in a fed state after rabeprazole pretreatment.
Key findings: Betaine HCl (1500 mg) restored only 12 to 13% of atazanavir exposure lost to PPI-induced hypochlorhydria in a fed state, demonstrating that food buffering capacity substantially limits betaine HCl effectiveness during meals.
Notes: Shows that the fasted-state reacidification results from prior studies do not translate well to fed conditions.
Paper content
This crossover trial tested whether betaine HCl (1500 mg) could rescue atazanavir absorption that was suppressed by rabeprazole-induced hypochlorhydria in a fed state. Rabeprazole reduced atazanavir Cmax and AUC by about 70%. Betaine HCl restored only 12 to 13% of the lost exposure, a far smaller recovery than what was achieved with betaine HCl in the fasted state in prior studies. The results show that food's buffering capacity substantially limits betaine HCl's ability to reacidify the stomach during meals.